In particular, glucagon‐like peptide‐1 receptor (GLP‐1R) targeting to potentiate this process is highly effective for the treatment of T2D, with GLP‐1R agonists (GLP‐1RAs) such as liraglutide, exenatide and semaglutide already in use successfully in the clinic.4 The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.